A new metabolic pathway for N,N-dimethyltryptamine.
N,N-Dimethyltryptamine (DMT) undergoes a major structural alteration when added to whole human blood or its red blood cells in vitro. A new high-pressure liquid chromatography (HPLC) peak is present in extracts of these treated tissues. The compound responsible for this peak has been identified by ultraviolet spectrophotometry and by mass spectrometry as dimethylkynuramine (DMK). The enzyme responsible for this appears to be different from tryptophan 2,3-dioxygenase and also from indoleamine 2,3-dioxygenase.
Hryhorczuk
L M
LM
Rainey
J M
JM
Frohman
C E
CE
Novak
E A
EA
D002250:Carbon Radioisotopes; D055598:Chemical Phenomena; D002621:Chemistry; D002851:Chromatography, High Pressure Liquid; D003891:Desipramine / Q000097:blood; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007735:Kynuramine / Q000031:analogs & derivatives / Q000097:blood; D013058:Mass Spectrometry; D004130:N,N-Dimethyltryptamine / Q000097:blood*; D010949:Plasma / Q000378:metabolism; D013056:Spectrophotometry, Ultraviolet; D014363:Tryptamines / Q000097:blood*
D002250:Carbon Radioisotopes; D014363:Tryptamines; D007735:Kynuramine; C047173:N,N-dimethylkynuramine; D003891:Desipramine; D004130:N,N-Dimethyltryptamine